Equillium Inc. (EQ)
EQ trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/0001193125-26-124143-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EQ on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001746466 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $41.1M |
| Net income | -$8.1M |
| Operating income | -$8.3M |
| Net margin | -19.6% |
| Operating margin | -20.1% |
| Revenue growth | +13.9% |
| Cash | $18.1M |
| Total assets | $25.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $53.3M cash; operating cash flow -$3.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 82,324,700 (2026-11-10); 60,893,283 a year earlier; 35,119,248 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Crowe LLP, Costa Mesa, California, United States; changed auditors 2 times in 24 months | 8-K 4.01 2025-10-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$4.6M | -$3.8M | $53.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$4.7M | -$4.1M | $57.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$5.3M | -$4.3M | $61.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$3.8M | -$3.1M | $30.3M | No debt tags | Needs four quarters | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | Not filed | -$4.2M | -$8.4M | $33.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$5.7M | -$3.0M | $11.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$8.7M | -$8.2M | $14.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | $4.4M | -$5.8M | -$3.3M | $18.1M | No debt tags | $41.1M | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-15 |
Source: SEC EDGAR submissions feed, 471 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.6% |
| 1 month | -2.3% |
| 3 months | -35.8% |
| Year to date | -16.8% |
| 1 year | +53.6% |
| From 52-week high | -59.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NRXP | NRX Pharmaceuticals Inc. | $2.15 | -1.83% | $93.8M |
| NBP | NovaBridge Biosciences | $0.7915 | -6.87% | $91.3M |
| RTSN | Retension Pharmaceuticals Inc. | $11.46 | -6.60% | $90.3M |
| PMVP | PMV Pharmaceuticals Inc. | $1.19 | -6.30% | $89.9M |
| ANIX | Anixa Biosciences Inc. | $2.55 | -2.67% | $88.6M |
| OGI | Organigram Global Inc. Common Shares | $0.7240 | -12.62% | $102.2M |
| CUE | Cue Biopharma Inc. | $14.10 | -12.53% | $102.4M |
| HURA | TuHURA Biosciences Inc. | $1.33 | -4.32% | $87.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier